RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a $25 price target on the company's stock.

January 29, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Luca Issi reaffirmed an Outperform rating on 4D Molecular Therapeutics and kept the price target at $25, indicating a positive outlook for the stock.
The reiteration of an Outperform rating by a prominent analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price. The maintained price target suggests that the analyst sees continued upside potential for the stock, which could encourage investors to maintain or establish positions in FDMT.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100